No single manufacturer can meet coronavirus vaccine global demand, says Moderna CEO

Cnbc | May 13, 2020

  • Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand.

  • Regeneron CEO Leonard Schleifer, whose company is developing an antibody drug against Covid-19, told CNBC that the problem isn’t with the physical distribution of a potential coronavirus drug but rather with the ability to meet demand.

  • Experimental vaccines will need to be mass produced and administered to more than 7.6 billion people around the world.


Moderna CEO Stephane Bancel said he hopes U.S. and international regulators approve several coronavirus vaccines from multiple companies, because no single manufacturer will be able to meet global demand.


“The odds that every program works are really low, obviously, but I really hope we have three, four, five vaccines, because no manufacturer can make enough doses for the planet,” Bancel said during CNBC’s Healthy Returns Virtual Summit.


Moderna has developed one of the leading coronavirus vaccine candidates in the world. The company is currently wrapping up phase one human trials on it in Seattle and is about to start phase 2 two trials, it announced last week. If it’s effective and safe to use, it could be ready for market in early 2021, the company said.


Bancel said Moderna is working closely with Dr. Anthony Fauci’s team at the National Institute of Allergy and Infectious Diseases as well as the Centers for Disease Control and Prevention to determine the best plan to distribute the vaccine, which could be ready in 12 to 18 months within the U.S.


On Tuesday, the U.S. Food and Drug Administration granted “fast track” designation to Moderna’s coronavirus vaccine, a move that speeds up the regulatory review process. Other companies racing to develop a vaccine include Pfizer and Inovio, which have already started clinical trials.


On Thursday, Moderna said it will soon begin phase two trials with 600 participants and is finalizing plans for a phase three trial as early as this summer.


Read More: U.S. STATES BUILD STOCKPILES OF MALARIA DRUG TOUTED BY TRUMP
 

Even as the company ramps up its manufacturing capacity so it can rapidly distribute doses if the vaccine proves effective against the virus and safe for humans, it won’t immediately have enough for everyone, Bancel told CNBC on Friday.


Regeneron CEO Leonard Schleifer, whose company is developing an antibody drug against Covid-19 with plans to enter human trials in June, told CNBC that the problem isn’t with the physical distribution of a potential coronavirus drug, which could be made available by major retail chains, but rather with the ability to meet demand. There are more than 7.6 billion people in the world, and it could take years to vaccinate enough people to achieve so-called herd immunity.


“The physical distribution aspect I think is more than adequate. I do think there will be a capacity issue,” Schleifer said.


Schleifer said multiple companies will need to succeed in the development of their coronavirus therapeutics because “the demand will far exceed the capacity.”


We simply cannot do this on an auction basis, whatever state and local area or company wants to pay the highest amount to get access, we can’t do it that way, it’s the role of federal, state and other global governments to ensure the drugs are distributed equitably.

-Regeneron CEO Leonard Schleifer


He said the company is trying to get its drug into patients within five months, which would be the fastest it’s ever done so. It took the company nine months to develop an antibody drug for Ebola, he said.


During a congressional hearing Tuesday, Fauci told lawmakers, “There’s no guarantee that the vaccine is actually going to be effective.” There are currently no proven treatments or vaccines against Covid-19.


“One of the big unknowns is, will it be effective? Given the way the body responds to viruses of this type, I’m cautiously optimistic that we will with one of the candidates get an efficacy signal,” Fauci said.


Read More: COVID-19 ANTI-VIRAL DRUG REMDESIVIR EFFECTIVE ON MONKEYS AND PEOPLE

Spotlight

This video looks at the structure of bacteriophages, their mode of action and their potential to treat bacterial infections.

Spotlight

This video looks at the structure of bacteriophages, their mode of action and their potential to treat bacterial infections.

Related News

Parallel's Surterra Wellness Stores to Introduce New Products Including Edibles in Florida

Prnewswire | August 31, 2020

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of edible products. Launch is dependent on regulatory approval of each of those products. Surterra Wellness, widely known for its line of whole flower, vaporizers, tincture oils, topical patches, theragels and lotions, is Parallel's leading cannabis retail brand for patients and customers aiming to improve their well-being in both Florida and Texas.

Read More

Vifor Pharma and Cara Therapeutics announces sign license agreement for IV Korsuva™* to treat dialysis patients with pruritus

Vifor Pharma and Cara Therapeutics, Inc. | October 20, 2020

Vifor Pharma and Cara Therapeutics, Inc. today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement. “With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal commercialization partner to bring IV Korsuva to dialysis patients across the country,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “In addition, we believe Vifor Pharma’s existing relationships with US dialysis providers will provide significant momentum for the launch and adoption of IV Korsuva, if approved. As a result of this agreement, we expect to focus Cara’s internal resources on our clinical programs for Oral Korsuva in atopic dermatitis, pre-dialysis CKD and additional pruritic conditions.”

Read More

PHARMACY MARKET

TrialCard Launches Engage HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement services for the following disciplines: Clinical Nurse Educators Field Reimbursement Managers Pharmaceutical Institutional, Sales, and Specialty Representatives Rare Disease Professionals Telepromotion Agents Medical Science Liaisons These augmented services strengthen TrialCard's original position in virtual detailing, which began several years ago. "TrialCard developed this suite of services to address for our clients the increasing number of "difficult to see" and "no see" HCPs," said Tom Heck, SVP of Commercial Solutions at TrialCard. "Engage HCP by TrialCard further solidifies our commitment to helping brands grow and thrive via non-traditional methods." Long before the COVID-19 global pandemic altered the traditional pharmaceutical selling cycle, pharma sales reps' access to HCPs had been decreasing for years. According to ZS's 2019 AffinityMonitor findings, only 47.3% of physicians engaged well with in-person pharma rep meetings, while just 9.6% of physicians engaged using digital tactics. TrialCard, a pioneer in digital HCP engagement, recognized this opportunity and began reaching out to physicians via digital channels years ago. "Many predict that it is unlikely society will ever return to pre-COVID-19 behavior," said Mark Bouck, President and CEO of TrialCard. "As HCPs become more accustomed and comfortable with digital communications, they will likely continue to become even less reliant on face-to-face interaction." "Our pharmaceutical sales reps enter the physician's office using technology instead of the front door," said Mike Davis, TrialCard's VP of Commercial Solutions. "While that technology is the backbone of our programs, our proven track record in supplementing a brand's field sales force is a result of the caliber of talent that we hire, the superior training and resources we provide, and the flexibility, experience, and expertise to create customized solutions for each client." About TrialCard TrialCard Incorporated is a full-service life sciences commercialization partner that provides comprehensive solutions that span the entire biopharmaceutical value chain. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. Founded in 2000, TrialCard provides commercialization needs for more than 160 life science customers and has connected over 35 million patients with more than $18 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina.

Read More